Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant.
Dig Liver Dis
; 36(10): 677-81, 2004 Oct.
Article
em En
| MEDLINE
| ID: mdl-15506667
ABSTRACT
BACKGROUND/AIMS:
Lamivudine efficiently inhibits hepatitis B virus replication and has been used to treat hepatitis B virus recurrence after orthotopic liver transplantation. Although effective, its use is hampered by viral breakthrough due to the appearance of hepatitis B virus drug-resistant strains. Aims of this work were to evaluate the inter- and intra-individual variations of lamivudine serum levels and the effects on the drug levels of the lamivudine-resistant hepatitis B virus mutant infection.METHODS:
Serum lamivudine concentration was measured by high-performance liquid chromatography. Polymerase chain reaction analysis and sequencing analysis of the reverse transcriptase area of the polymerase was performed on each sample using specific primers. A polymerase chain reaction-enzyme-linked immunosorbent assay was used to differentiate between wild-type hepatitis B virus and lamivudine-resistant hepatitis B virus strain.RESULTS:
Lamivudine serum levels presented minor inter- and intra-individual fluctuations along time, with an important increase at the time of the hepatitis flare-up due to the hepatitis B virus mutant presence. When the wild-type hepatitis B virus briefly reappeared as a mixed population, the titre of lamivudine dropped to below the detection level.CONCLUSIONS:
While lamivudine serum levels appears stable when the anti-viral efficacy is fully achieved, important fluctuations are present according to the type of viral population, with a considerable decrease possibly due to the presence of the wild-type virus.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vírus da Hepatite B
/
Lamivudina
/
Hepatite B
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article